Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

References

• Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171–7.
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414–20.
   PubMed Web of Science ®Google Scholar
• Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414–22.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56–66.
   PubMedGoogle Scholar
• Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547–53.
   PubMedGoogle Scholar
• Quail MA,Russell RK, Van Limbergen JE, Rogers P, Drummond HE, Wilson DC, Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756–9.
   PubMedGoogle Scholar
• Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162–9.
   PubMed Web of Science ®Google Scholar
• Diamanti A, Colistro F, Basso MS, Papadatou B, Francalanci P, Bracci F, Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008;14:1229–35.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006;41:720–5.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392–8.
   PubMed Web of Science ®Google Scholar
• Sipponen T, af Björkesten C-G, Färkkilä M, Nuutinen H, Savilahti E, Kolho K-L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2009; Epub ahead of print.
   PubMedGoogle Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2–6.
   PubMedGoogle Scholar
• Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004;36:467–70.
   PubMedGoogle Scholar
• Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Walkiewicz D, Werlin SL, Fish D, Scanion M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669–73.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera S, Vera I, McNicholl AG, Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190–8.
   PubMed Web of Science ®Google Scholar
• Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35–40.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, Vos MD, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2009; Epub ahead of print.
   PubMedGoogle Scholar
• Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart AH, Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflamm Bowel Dis 2009; Epub ahead of print.
   Google Scholar
• Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H. Factors predicting the outcome of disease activity assessment in Crohn's disease. Inflamm Bowel Dis 2009;15:1859–66.
   PubMedGoogle Scholar